The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase II Study Of PCSK9si

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Tuesday, November 15, 2016, at 3:00 p.m., Eastern Time, to review data from the ORION-1 study of the Company’s PCSK9 synthesis inhibitor (PCSK9si). During the call, the Company’s management and PCSK9si product teams, as well as distinguished outside experts, will review data from the ongoing ORION-1 Phase 2 study of PCSK9si, which will have been presented earlier in the day in a Late-Breaking Clinical Trials session at the American Heart Association’s Scientific Sessions 2016.

The dial-in information to access the call is listed below:

U.S./Canada: (877) 359-9508
International: (224) 357-2393
Conference ID: 1645474

A taped replay will be available at 6:00 p.m., Eastern Time, following the conference call for one week. The replay may be accessed by dialing:

U.S./Canada: (855) 859-2056
International: (404) 537-3406
Conference ID: 1645474

This call is being webcast and can be accessed in the “Investors” section of The Medicines Company website. A replay of the webcast will also be available.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose—to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.